Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hanying Xu
Institutions:
Changchun University of Chinese Medicine,
The Affiliated Hospital to Changchun University of Chinese Medicine
Observed institutions:
Changchun University of Chinese Medicine,
The Affiliated Hospital to Changchun University of Chinese Medicine
ORCID:
0000-0003-1380-7260
Observed ORCID:
0000-0003-1380-7260
OpenAlex ID:
A5025024468
Traditional Chinese Medicine and Ferroptosis in Intracerebral Hemorrhage: A Potential Therapeutic Approach
2025
·
Hanying Xu
, Jing Lu
, et al.
·
Drug Design Development and Therapy
·
9
PDF
Gui-Pi-Tang Defers Skeletal Muscle and Cardiac Muscle Aging by Promoting Mitochondrial Remodeling
2025
·
Changjiu Cai
, Manying Wang
, et al.
·
Drug Design Development and Therapy
·
3
From Mechanistic Evidence to Clinical Translation: A Narrative Review of Chinese Herbal Medicine for Insomnia
2026
·
Ximing Li
, Hanying Xu
, et al.
·
Drug Design Development and Therapy
PDF
Supplementary Table from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
Supplementary Figure from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
PDF
Supplementary Figure from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
PDF
Supplementary Figure from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
Supplementary Figure from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
PDF
Supplementary Data from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
Supplementary Figure from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
Supplementary Figure from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
PDF
Supplementary Figure from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
Data from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
Data from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
Supplementary Figure from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
PDF
Supplementary Figure from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
Supplementary Figure from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
Supplementary Figure from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
Supplementary Figure from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
PDF
Supplementary Figure from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
PDF
Supplementary Figure from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
2023
·
Mingzhi Zhang
, Dan Chen
, et al.
Show more works
View as search
Works count:
21
Citation count:
12
H-index:
2
I10-index:
Year
Topic
Type